15-43197346-T-C
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_001114134.2(EPB42):āc.2032A>Gā(p.Asn678Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000665 in 1,614,098 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001114134.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
EPB42 | NM_001114134.2 | c.2032A>G | p.Asn678Asp | missense_variant | 13/13 | ENST00000441366.7 | NP_001107606.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
EPB42 | ENST00000441366.7 | c.2032A>G | p.Asn678Asp | missense_variant | 13/13 | 1 | NM_001114134.2 | ENSP00000396616 | P1 | |
EPB42 | ENST00000567019.2 | n.1538A>G | non_coding_transcript_exon_variant | 8/8 | 1 | |||||
EPB42 | ENST00000648595.1 | c.2122A>G | p.Asn708Asp | missense_variant | 13/13 | ENSP00000497777 | ||||
EPB42 | ENST00000540029.5 | c.1798A>G | p.Asn600Asp | missense_variant | 12/12 | 2 | ENSP00000444699 |
Frequencies
GnomAD3 genomes AF: 0.000414 AC: 63AN: 152208Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000346 AC: 87AN: 251488Hom.: 0 AF XY: 0.000316 AC XY: 43AN XY: 135922
GnomAD4 exome AF: 0.000691 AC: 1010AN: 1461890Hom.: 0 Cov.: 30 AF XY: 0.000671 AC XY: 488AN XY: 727248
GnomAD4 genome AF: 0.000414 AC: 63AN: 152208Hom.: 0 Cov.: 32 AF XY: 0.000430 AC XY: 32AN XY: 74362
ClinVar
Submissions by phenotype
Hereditary spherocytosis type 5 Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 30, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 26, 2023 | - - |
not provided Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 14, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jul 08, 2022 | BP4 - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 08, 2021 | The c.2122A>G (p.N708D) alteration is located in exon 13 (coding exon 13) of the EPB42 gene. This alteration results from a A to G substitution at nucleotide position 2122, causing the asparagine (N) at amino acid position 708 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
EPB42-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 12, 2022 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at